Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06721494 · ClinicalTrials.gov registry record · Phase 2
A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine
A Phase 2 study of Methamphetamine Abuse and Methamphetamine Disorders, sponsored by Clear Scientific.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06721494: Recruiting Phase 2 study of Methamphetamine Abuse and Methamphetamine Disorders, sponsored by Clear Scientific.
NCT06721494 is a Phase 2 study of Methamphetamine Abuse and Methamphetamine Disorders that is actively recruiting participants, run by Clear Scientific. The registered enrollment target is 40 participants, below the 206-participant average among 15 other Methamphetamine Abuse trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06721494, a Phase 2 study of Methamphetamine Abuse and Methamphetamine Disorders, is actively recruiting participants, sponsored by Clear Scientific.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).
Primary Outcome
Physical examinations
Conditions Studied
Interventions
- DRUG Methamphetamine
- DRUG Sterile Saline
- DRUG CS-1103
Study Locations (1)
California
- California Clinical Trials Medical Group - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-02-05 |
| Est. Completion | 2026-09-11 |
| Phase | Phase 2 |
What NCT06721494 shows while recruiting
NCT06721494 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 206-participant average among 15 other Methamphetamine Abuse trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Methamphetamine Abuse appearing as the primary indexed condition, and to 3 interventions - of which Methamphetamine is the first listed.
NCT06721494 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06721494 about?
NCT06721494 is a clinical study titled "A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine". The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose ...
What is the current status of trial NCT06721494?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-02-05. Estimated completion is 2026-09-11.
What conditions does trial NCT06721494 study?
This clinical trial studies the following conditions: Methamphetamine Abuse, Methamphetamine Disorders, Methamphetamine Intoxication.
What interventions are being tested in trial NCT06721494?
The interventions under investigation include: Methamphetamine (DRUG), Sterile Saline (DRUG), CS-1103 (DRUG).
Who is sponsoring clinical trial NCT06721494?
This trial is sponsored by Clear Scientific, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06721494 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06721494's enrollment target sits among peer trials
40 11th of 15 higher than 4 of 15 other Methamphetamine Abuse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Methamphetamine Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine for Methamphetamine Use Disorder
RECRUITING · Phase 2
-
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
COMPLETED · Phase 2
-
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
RECRUITING · Phase 3
-
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
RECRUITING · NA
-
Theta Burst TMS for Treatment of Methamphetamine Use Disorder
RECRUITING · NA
-
rTMS for Craving in Methamphetamine Use Disorder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI